Drug Trial Radar · NCT04708496
Optimizing Malaria Treatment for HIV-Malaria Co-infected Individuals
Last checked: Nov 20, 2026Latest source record: Jan 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
888
Planned (sponsor's estimate)
Start
Jan 18, 2021
Primary completion
Jan 2024
Study completion Mar 2024
Sponsor
- Lead sponsor
- Makerere UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Optimal is a Randomized clinical trial to optimize treatment of malaria in HIV -malaria co infected patients. It has been demonstrated that, when the antimalarial drug Artemether Lumefantrine is co administered with Efavirenz based ART in HIV-malaria co-infected individuals, sub therapeutic levels of the drug are achieved hence resulting in poor malaria treatment outcomes. The study then hypothesizes that, : HIV-malaria co-infected individuals receiving efavirenz-based ART plus a double-dose or 5-day course of artemether-lumefantrine will achieve higher and adequate artemether-lumefantrine serum concentrations with adequate 42-day treatment outcomes compared to individuals with HIV-malaria co-infection receiving efavirenz-based ART plus a standard-dose of artemether-lumefantrine.
Conditions
- HIV Coinfection
- Malaria
Interventions
Artemether-lumefantrineDrug
A three-arm single blind Randomized Clinical Trial in which HIV-malaria co-infected individuals with uncomplicated malaria receiving efavirenz-based ART will be randomized to one of three arms; a standard dose of artemether-lumefantrine, or a double dose of artemether-lumefantrine, or a 5-day course of artemether-lumefantrine for treatment of uncomplicated malaria. Participants will be followed up for 42 days to determine safety, drug pharmacokinetics and malaria treatment outcomes. The 4th objective focuses on the interaction between Dolutegravir and Artemether Lumefantrine hence this will be a single blind pharmacokinetic trial among HIV-malaria co-infected individuals receiving Dolutegravir based ART and standard dose of artemether-lumefantrine for treatment of uncomplicated malaria.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Measure of malaria treatment outcome adjusted by genotyping and classified as reinfection or recrudescence.Time frame: Day 42
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Infectious Diseases Institute
Kampala, Uganda · Completed
Tororo District Hospital
Tororo, Uganda · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.